Muhammad ShaalanBegMDMS

PubMed

• Targeted therapies in advanced biliary malignancies: a clinical review.
  Udhayvir S Grewal, Shiva J Gaddam, Muhammad S Beg, Timothy J Brown
  Expert Review of Anticancer Therapy. 2024-09-01
• 1 citations
  Remote Monitoring and Data Collection for Decentralized Clinical Trials.
  Bobby Daly, Otis W Brawley, Mary K Gospodarowicz, Olufunmilayo I Olopade, Lola Fashoyin-Aje
  JAMA Network Open. 2024-04-01
• 2 citations
  Modernize Precision Oncology With Decentralized Trial Tools.
  Muhammad Shaalan Beg, Vivek Subbiah
  JAMA Oncology. 2024-04-01

Journal Articles

• Feasibility of Wearable Physical Activity Monitors in Patients With Cancer  
  Gupta A, Stewart T, Bhulani N, Dong Y, Rahimi Z, Crane K, Rethorst C, Beg MS, JCO Clinical Cancer Informatics, 1/1/2018
• Impact of concurrent medication use on pancreatic cancer survival-SEER-Medicare analysis  
  Beg MS, Gupta A, Sher D, Ali S, Khan S, Gao A, Stewart T, Ahn C, Berry J, Mortensen EM, Am J Clin Oncol, 1/10/2017
• The Promise of Wearable Physical Activity Monitors in Oncology Practice  
  Beg MS, Gupta A, Stewart S, Rethorst C, Journal of Oncology Practice, 1/1/2017
• Plasma leptin levels and risk of incident cancer: Results from the Dallas Heart Study  
  Gupta A, Herman Y, Ayers C, Beg MS, Lakoski SG, Abdulla SM, Johnson DH, Neeland IJ, PLoS One, 1/1/2016
• Yttrium-90 radioembolization of hepatic metastases from colorectal cancer  
  Raval M, Bande D, Pillai AK, Blaszkowsky LS, Ganguli S, Beg MS, Kalva SP, Front Oncol, 1/1/2014
• Predictive factors for early aspiration in liver abscess  
  Khan R, Hamid SS, Abid S, Jafri W, Abbas Z, Islam M, Shah H, Beg MS, World J Gastroenterol, 1/1/2008
• Join now to see all

Abstracts/Posters

• A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, admi...
  Sarantopoulos J, Beg MS, Fotopoulos G, Taverna JA, Anthony SP, Weitman SD, Warner SL, Mouritsen L, Bearss D, Smith S, Beever H, Khemka V, J Clin Oncol, 1/1/2018
• A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresect...
  Sahai V, Griffith KA, Beg MS, Zalupski M, J Clin Oncol, 1/1/2018
• Impact of palliative care consults on racial disparity in do-not resuscitation (DNR) orders at an urban safety net hospital.
  Bhulani N, Gupta A, Paulk ME, Donnell K, Harvey V, Cox J, Cox JV, Verma UN, Sanjeevaiah A, Cheedella NK, Khosama L, Arriaga YE, Syed SK, Kazmi SA, Beg MS, J Clin Oncol, 1/1/2018
• Does timing of palliative care consults impact end-of-life health services utilization in pancreatic cancer patients?
  Bhulani N, Gao A, Gupta A, Ahn C, Paulk E, Houck S, Li JJ, Guenther CM, Kazmi MA, Beg MS, J Clin Oncol, 1/1/2018
• The effects of pioglitazone treatment on pancreatic cancer-related insulin resistance.
  Stern J, Arriaga YE, Gupta A, Verma UN, Karri S, Syed SK, Khosama L, Mansour JC, Scherer P, Beg MS, J Clin Oncol, 1/1/2017
• Interaction between regorafenib and warfarin therapy.
  Beg MS, Khosama L, Conley S, Arriaga YE, Syed SK, Karri S, Verma UN, J Clin Oncol, 1/1/2017
• SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.
  Sohal D, McDonough SL, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, Guthrie K, Lowy AM, Philip PA, Hochster HS, J Clin Oncol, 1/1/2017
• Phase 1 study of ARQ 761, a B-lapachone analog that promotes NQO1-mediated programmed cancer cell necrosis.
  Gerber DE, Bisen AK, Beg MS, Frankel AE, Fatunde O, Fattah F, Arriaga YE, Dowell J, Meek C, Bolluyt J, Sarode V, Luo X, Schwartz BE, Boothman DA, Leff R, J Clin Oncol, 1/1/2017
• Feasibility of wearable physical activity monitors in cancer patients (PAMCaP).
  Beg MS, Steart T, Gupta A, Dong Y, Rahimi Z, Paul T, Crane K, Rethorst C, J Clin Oncol, 1/1/2017
• Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial.
  Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial., J Clin Oncol, 1/1/2017
• A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.
  Sohal D, McDonough SL, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, Guthrie KA, Lowy AM, Philip PA, Hochster HS, J Clin Oncol, 1/20/2016
• A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).
  Kim RD, Azad NS, Morse M, Tan BR, Poplin E, Beatson MA, Mavroukakis S, Cui K, Arlen PM, Beg MS, J Clin Oncol, 1/20/2016
• A liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.
  Hong DS, Kang YK, Brenner AJ, Sachdev JC, Ejadi S, Borad MJ, Kim TY, Lim HY, Park K, Becerra C, Bader AG, Stoudemire J, Smith S, Beg MS, J Clin Oncol, 1/20/2016
• A prospective analysis of individual body fat depots and risk of developing cancer: Insights from the Dallas heart study.
  Gupta A, Pandey A, Ayers C, Beg MS, Lakoski SG, Vega GL, Grundy SM, Johnson DH, Neeland IJ, J Clin Oncol, 1/20/2016
• Impact of concurrent medications use on outcome of pancreatic cancer: SEER Medicare analysis.
  Beg MS, Stewart T, Gao A, Ahn C, Berry J, Mortensen E, J Clin Oncol, 1/20/2016
• First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.
  Beg MS, Hong DS, Sachdev JC, Brenner J, Borad MJ, Ho YL, Kim TY, Becerra C, Park K, Bader AG, Stoudemire J, Smith S, Kim S, Kang YK, J Clin Oncol, 1/20/2016
• Chemotherapy outcomes for unresectable and metastatic biliary tract cancers (BTC): Role of fluoropyrimidine (FP) chemotherapy--A retrospective analysis.
  Alattar ML, Levin P, Beg MS, Verma U, Arriaga Y, Syed SK, Karri S, J Clin Oncol, 1/20/2016
• Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).
  Khan SA, Ci B, Gerber DE, McFadden DG, Beg MS, Xie Y, Kurian P, Cabanillas ME, Busaidy NL, Sherman SI, Heilmann A, Ross JS, Bailey M, Burtness B, Ali SM, J Clin Oncol, 1/1/2016
• Racial and sex disparities in changing trends of squamous cell cancer of the anus (SSCA).
  Gupta A, Zhu H, Christie A, Meyer JJ, Khan SA, Beg MS, J Clin Oncol, 1/1/2016
• Comprehensive genomic profiling (CGP) to assess mutational load in gastric and esophageal adenocarcinomas: Implications for immunotherapies.
  Frampton GM, Schrock AB, Chalmers ZR, Sun J, Ennis R, Gowen K, Beg MS, Rubinson DA, Yelensky R, Stephens PJ, Miller VA, Ross JS, Ali SM, Klempner SJ, J Clin Oncol, 1/1/2016
• A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic color...
  Kim RD, Azad NS, Morse M, Tan BR, Poplin E, Beatson MA, Mavroukakis S, Cui K, Arlen PM, Beg MS, J Clin Oncol, 1/1/2016
• A phase II multicenter study of the chimeric monoclonal antibody NEO102 (N) in adults with refractory colorectal cancer (CC).
  Beg MS, Morse M, Tan BR, Kim RD, Poplin E, Azad NS, Mavroukakis S, Beatson MA, Arlen PM, J Clin Oncol, 1/20/2015
• A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or lo...
  Duffy AG, Beg MS, Greten TF, Beatson MA, Mavroukakis S, Patel SPP, Morse MA, Arlen PM, J Clin Oncol, 1/20/2015
• A Phase I/IIA multicenter clinical trial of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic and colorectal cancer.
  Beg MS, Morse M, Patel SP, Azad NS, Mavroukakis S, Beatson M, Arlen PM, J Clin Oncol, 1/20/2015
• Phase 1 correlative study of ARQ761, a B-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis.
  Gerber D, Arriaga Y, Beg MS, Dowell JE, Schiller JH, Frankel AE, Leff R, Meek C, Bolluyt J, Fatunde O, Martinez RT, Vo P, Fattah F, Sarode V, Zhou Y, Xie Y, McLeod, B...., EJC, 1/1/2015
• Join now to see all

Lectures

• A phase II clinical trial of the phosphatidylserine targeting antibody, bavituximab, in combination with pembrolizumab in patients with advanced hepatocellular carcinoma. 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
• Molecular Mechanisms of Pancreatic Cancer Metabolism 
  Plano, TX - 1/1/2018
• Use Social Media to increase your influence. 
  Alexandria, VA, 2018; Dallas, TX, 2018 - 1/1/2018
• Molecular targeted therapies for colorectal cancer 
  Daytona Beach, FL - 1/1/2017
• Challenges in Pancreatic cancer clinical Trials 
  Vanderbilt University, Nashville, TN - 1/1/2017
• Pancreatic Cancer management at the VA 
  VAMC, Dallas, TX - 1/1/2017
• NQO1 Mediated Kiss of Death therapy for pancreatic cancer 
  San Francisco, CA - 1/1/2017
• The role of maintenance chemotherapy in metastatic pancreatic cancer 
  Orlando, FL - 1/1/2016
• NQO1 �Kiss of Death�, clinical trial design. 
  San Diego, CA - 1/1/2016
• Clinical trials design for locally advanced pancreatic Cancer 
  Boston, MA - 1/1/2016
• Clinical trial toxicity assessment and reporting 
  Dallas, TX - 1/1/2015
• Hepatocellular Cancer 
  Dallas, TX - 1/1/2015
• Exploiting the NQO1 �Kiss of Death� as a therapeutic strategy for Pancreatic cancer 
  MD Anderson Cancer Center, Houston, TX - 1/1/2015
• Perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. 
  Chicago, IL - 1/1/2015
• A Phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis 
  Barcelona, Spain - 1/1/2015
• Colorectal Cancer 
  Dallas, TX - 1/1/2014
• Evidence based management of metastatic colon cancer 
  Elkhart, IN, 2014; Reno, NV, 2014 - 1/1/2014
• A Phase 1 study of MRX-34, first in human, first in class liposomal micro-RNA-34 
  San Diego, CA - 1/1/2014
• Colorectal Cancer Update 
  Austin, TX - 1/1/2014
• Impact of screening on presentation and survival of colorectal cancer 
  Cincinnati, OH - 1/1/2007
• Do racial differences predict survival amongst VA patients with colon cancer 
  Cincinnati, OH - 1/1/2006
• Join now to see all

Other

• Pancreatic cancer risks and solutions 
  Beg MS, Dr Oz Show
  1/1/2018
• Life Lessons From a Man With Stage 4 Pancreatic Cancer - Men's Health 
  Beg MS, Mens Health Magazine
  1/1/2017
• Promise of wearable activity monitors in oncology practice 
  Beg MS, American Society of Clinical Oncology JOP Podcast
  1/1/2017
• Is wearable technology coming of age in Oncology? 
  Beg MS, ASCO Post
  1/1/2017
• Plugged In To DFW-CBS Dallas: Pancreatic cancer awareness television interview 
  Beg MS, CBS Dallas
  1/1/2017
• Doctor discusses colon cancer screening- Television Interview 
  Beg MS, NBC DFW News
  1/1/2017
• Doctor Joins Volunteers in Fighting for Our Cause 
  Beg MS, Volunteer Appreciation Month
  www.pancan.org
  1/1/2016
• UT Southwestern docs using South American tree to fight tumors- Television interview 
  Beg MS, WFAA News
  1/1/2016
• Mipsagargin Phase 2 Abstract Review. (Video interview) 
  Beg MS, GenSpera, Inc
  1/1/2015
• Pancreatic cancer awareness television interview 
  Beg MS, CBS Dallas-Plugged In To DFW-CBS Dallas
  1/1/2015
• GI Cancers Symposium 2015: Colorectal Carcinoma abstracts review for 
  Beg MS, MedTALKS Oncology TV
  1/1/2015
• If you�re over 50, it�s time for a colonoscopy 
  Beg MS, UTSW Blog Stories and Insights
• 8 common myths about colon cancer 
  Beg MS, UTSW Blog Stories and Insights
• What to expect if you have colon cancer 
  Beg MS, UTSW Blog Stories and Insights
• Joining together to fight pancreatic cancer 
  Beg MS, UTSW Blog Stories and Insights
• How does nutrition affect pancreatic cancer? 
  Beg MS, UTSW Blog Stories and Insights
• Processed meat and cancer: What�s the real risk? 
  Beg MS, UTSW Blog Stories and Insights
• 10 years of surviving colon cancer: Charles� story 
  Beg MS, UTSW Blog Stories and Insights
• 6 ways millennials and Gen Xers can reduce their colorectal cancer risk 
  Beg MS, UTSW Blog Stories and Insights
• Join now to see all